Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Licenses Knockout Mouse Technology to Lilly

NEW York, Nov. 16 – Lexicon Genetics has sublicensed aspects of its proprietary knockout mouse technology to Eli Lilly, the company announced Thursday.

The non-exclusive license covers the positive-negative selection and isogenic DNA technologies that Lexicon has licensed from academic researchers for its proprietary mouse gene function validation experiments.

Lilly plans to use the knockout mouse technology in its drug discovery and target validation research. The parties did not disclose the financial terms of the agreement.

" We are pleased that Lilly has joined our growing list of sublicensees for Lexicon's powerful gene-targeting technology," said Randall Riggs, Lexicon’s senior vice president of business development said in a statement. “It has become the gold standard for target validation."

Lexicon’s other sublicensees for this technology include Bristol-Myers Squibb, Pfizer, Roche Bioscience, Schering-Plough Research Institute, Millennium Pharmaceuticals, Genentech, Amgen, Ligand Pharmaceuticals, American Home Products, DuPont Pharmaceuticals, and Biogen.

This new agreement follows on the heels of rival Deltagen’s Monday announcement that it had filed an antitrust countersuit against Lexicon. Lexicon has sued Deltagen for patent infringement on positive-negative selection and its isogenic DNA technologies, and this suit is pending in federal court.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.